Jazz Pharmaceuticals Completes U.S. Divestiture Of Sunosi To Axsome Therapeutics, What's Next?

Jazz Pharmaceuticals plc JAZZ has completed the divestiture of Sunosi (solriamfetol) in the U.S. to Axsome Therapeutics, Inc. AXSM.

Deal Details

Under the terms of the agreement, Jazz received an upfront payment of $53 million, and will receive a high single-digit royalty on Axsome's U.S. net sales of Sunosi in current indications and a mid-single-digit royalty on Axsome's U.S. net sales of Sunosi in future indications.

Axsome said earlier that it expects to finance the transaction via its existing $300 million term loan facility with Hercules Capital Inc.

Why It Matters?

"The divestiture of Sunosi enables us to sharpen our focus on the strategic areas where we see the most opportunity for sustainable growth and enhanced shareholder value," Bruce Cozadd, chairman and CEO of Jazz Pharmaceuticals, said.

Sunosi is dual-acting dopamine, and norepinephrine reuptake inhibitor (DNRI) indicated to improve wakefulness in adult patients with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA).

Sunosi was approved by the FDA in 2019 and by the European Medicines Agency (EMA) in 2020.

Based on further growth potential in the current indication, and potential new indications, the Company estimates a peak revenue potential of greater than $1 billion for Sunosi.

What's Next?

Cozadd said that the Dublin-based company will continue to invest in "our highest strategic priorities, driving the transformation of Jazz to an innovative, global biopharmaceutical leader, and delivering improved top- and bottom-line growth through operational excellence."

Subject to the satisfaction of conditions to closing, the ex-U.S. transaction is expected to close within 60 days.

Photo: Courtesy of NordWood Themes on Unsplash

Posted In: CannabisM&ANewsAsset SalesSmall CapMarketsAsset SaleBruce CozaddSunosi

Missed the first wave of cannabis investments? Don’t make that mistake again.

Experts believe cannabis stocks have found their floor and are now poised for unprecedented growth.

Join Benzinga PotProfits. Our in-house canna stock expert, Michael Berger, is on a mission to uncover the most promising cannabis stocks poised for growth, even in a dull market. He leaves no bud unturned to bring you the juiciest potential double-digit opportunities!

Just this year, the PotProfits portfolio has seen smoking-hot gains like:

  • 47.10% with $GTBIF
  • 40.23% with $TCNNF
  • 21.50% with $VFF

But here's the kicker: Michael is about to release his next potential winners, and he's chomping at the bit to share these ticker symbols with you ASAP.

Don't miss out on the green rush!